DexCom (MEX:DXCM) Cyclically Adjusted Revenue per Share: MXN133.48 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:DXCM DexCom Inc MEX:DXCM
87 GF Score
Price MXN1,529.00
GF Value MXN1,681.67
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is DexCom Cyclically Adjusted Revenue per Share?

DexCom MEX:DXCM -0.57% 87 Cyclically Adjusted Revenue per Share is MXN133.48 as of Jun. 2026. GuruFocus rates MEX:DXCM with a GF Score™ of 87/100 and a GF Value™ of MXN1,681.67 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

DexCom's adjusted revenue per share for the three months ended in Jun. 2026 was MXN58.524. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN133.48 for the trailing ten years ended in Jun. 2026.

During the past 12 months, DexCom's average Cyclically Adjusted Revenue Growth Rate was 21.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 23.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 26.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 32.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of DexCom was 39.20% per year. The lowest was 23.20% per year. And the median was 35.25% per year.

As of today (2026-08-22), DexCom's current stock price is MXN1529.00. DexCom's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN133.48. DexCom's Cyclically Adjusted PS Ratio of today is 11.45.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DexCom was 65.27. The lowest was 8.79. And the median was 29.54.


DexCom  (MEX:DXCM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

DexCom's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1529.00/133.48
=11.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DexCom was 65.27. The lowest was 8.79. And the median was 29.54.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


DexCom Cyclically Adjusted Revenue per Share Related Terms


DexCom Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for DexCom's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Cyclically Adjusted Revenue per Share Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.28 65.26 61.52 109.99 118.80

DexCom Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.56 116.10 118.80 132.52 133.48

MEX:DXCM vs GEHC, STE, ZBH: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, DexCom's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DexCom's Cyclically Adjusted PS Ratio falls into.


MEX:DXCM
87GF Score
DexCom Inc MEX:DXCM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DexCom's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=58.524/333.9520*333.9520
=58.524

Current CPI (Jun. 2026) = 333.9520.

DexCom Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 8.541 241.428 11.814
201612 10.443 241.432 14.445
201703 7.862 243.801 10.769
201706 8.821 244.955 12.026
201709 9.660 246.819 13.070
201712 12.487 246.524 16.915
201803 9.594 249.554 12.839
201806 13.325 251.989 17.659
201809 13.811 252.439 18.271
201812 18.684 251.233 24.836
201903 15.064 254.202 19.790
201906 17.733 256.143 23.120
201909 21.145 256.759 27.502
201912 23.565 256.974 30.624
202003 25.236 258.115 32.651
202006 26.878 257.797 34.818
202009 27.802 260.280 35.671
202012 28.491 260.474 36.528
202103 24.672 264.877 31.106
202106 27.736 271.696 34.091
202109 31.070 274.310 37.825
202112 33.193 278.802 39.759
202203 29.205 287.504 33.923
202206 33.237 296.311 37.459
202209 36.356 296.808 40.906
202212 37.308 296.797 41.978
202303 31.937 301.836 35.335
202306 34.618 305.109 37.891
202309 39.792 307.789 43.174
202312 42.100 306.746 45.834
202403 36.681 312.332 39.220
202406 44.143 314.175 46.922
202409 47.723 315.301 50.546
202412 57.101 315.605 60.420
202503 52.012 319.799 54.314
202506 53.374 322.561 55.259
202509 54.452 324.800 55.986
202512 56.856 324.054 58.593
202603 54.607 330.213 55.225
202606 58.524 333.952 58.524

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN133.48 mean?
DexCom (MEX:DXCM) has a Cyclically Adjusted Revenue per Share of MXN133.48 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DexCom and its competitors.
Is DexCom's Cyclically Adjusted Revenue per Share too high?
DexCom's current Cyclically Adjusted Revenue per Share is MXN133.48. Overall, DexCom has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Cyclically Adjusted Revenue per Share compare to GEHC and STE?
DexCom's Cyclically Adjusted Revenue per Share of MXN133.48 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DexCom and its competitors. DexCom's current Cyclically Adjusted Revenue per Share is MXN133.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (MEX:DXCM) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,681.67, compared to a current price of MXN1,529.00 — trading 9.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN133.48. DexCom's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For DexCom (MEX:DXCM), the current Cyclically Adjusted Revenue per Share is MXN133.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (MEX:DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of MXN1,529.00 is trading 9.1% below its estimated GF Value™ of MXN1,681.67. GuruFocus considers DexCom to be Modestly Undervalued.

Key valuation signals for MEX:DXCM:

  • Cyclically Adjusted Revenue per Share: MXN133.48
  • GF Value™: MXN1,681.67 vs. price of MXN1,529.00 (9.1% below fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the MEX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
87GF Score

Get the complete analysis for MEX:DXCM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,529.00
Price
MXN1,681.67
GF Value